<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050670</url>
  </required_header>
  <id_info>
    <org_study_id>17224</org_study_id>
    <secondary_id>I8F-MC-GPHI</secondary_id>
    <nct_id>NCT04050670</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide Concentrations at Different Injection Sites in Participants With Different Body Sizes</brief_title>
  <official_title>Effect of Injection Site on the Relative Bioavailability of a Single Dose of Tirzepatide in Subjects With Low and High Body Mass Indices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the amount of tirzepatide that gets into the blood
      stream and how long it takes the body to get rid of it, when injected under the skin of the
      upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and
      females with different body sizes. The tolerability of tirzepatide will be evaluated and
      information about any side effects experienced will be collected. For each participant, the
      study will last about 20 weeks, including screening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 13, 2019</start_date>
  <completion_date type="Actual">April 3, 2020</completion_date>
  <primary_completion_date type="Actual">April 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide</measure>
    <time_frame>Predose through approximately Day 36 postdose</time_frame>
    <description>PK: AUC of Tirzepatide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of Tirzepatide</measure>
    <time_frame>Predose through approximately Day 36 postdose</time_frame>
    <description>PK: Cmax of Tirzepatide</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tirzepatide - Upper Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered subcutaneously (SC) to the upper arm of healthy participants in one of three study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide - Thigh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered SC to the thigh of healthy participants in one of three study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide - Abdomen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tirzepatide administered SC to the abdomen of healthy participants in one of three study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Tirzepatide administered SC</description>
    <arm_group_label>Tirzepatide - Abdomen</arm_group_label>
    <arm_group_label>Tirzepatide - Thigh</arm_group_label>
    <arm_group_label>Tirzepatide - Upper Arm</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females of nonchildbearing potential as determined by medical
             history, physical examination, and other screening procedures

          -  Are between the body mass index (BMI) of 18.5 and 45.0 kilograms per meter squared
             (kg/mÂ²), inclusive, at screening

          -  Are agreeable to receiving study treatment by injections under the skin

        Exclusion Criteria:

          -  Have known allergies to tirzepatide or related compounds

          -  Have a personal or family history of medullary thyroid carcinoma or have multiple
             endocrine neoplasia syndrome type 2

          -  Have a history or presence of pancreatitis (history of chronic pancreatitis or
             idiopathic acute pancreatitis), elevation in serum amylase or lipase or
             gastrointestinal (GI) disorder (eg, relevant esophageal reflux or gall bladder
             disease) or any GI disease which impacts gastric emptying (eg, gastric bypass surgery,
             pyloric stenosis, with the exception of appendectomy) or could be aggravated by
             glucagon-like peptide-1 (GLP-1) analogs or dipeptidyl peptidase IV (DPP-IV) inhibitors

          -  Have a prior history of malignant disease(s) in the past 5 years prior to screening

          -  Smoke more than the equivalent of 10 cigarettes per day

          -  Is a known user of drugs of abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 15, 2020</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LY3298176</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

